You are here

Optimizing Atorvastatin-pretreated MSCs for AMI Treatment

Previous studies from the labs of Li Qian (University of North Carolina at Chapel Hill, USA) and Yue‐Jin Yang (Fuwai Hospital, Beijing, China) demonstrated how the combination of atorvastatin (ATV) and ATV‐pretreated mesenchymal stem cells (ATV‐MSCs) at one week post‐acute myocardial infarction (AMI) promoted MSC recruitment and survival. Now, the team returns with a new STEM CELLS Translational Medicine article in which they now establish that multiple intravenous administrations of ATV‐MSCs combined with intensive ATV administration at the mid‐term stage of AMI leads to optimal results. Overall, Xu et al. believe that the translational potential of this study to be “promising, straightforward, and enormous”.